The p53 pathway is partially abrogated in more than one-half of tumors through the inactivation of various signaling or effector components. Several recent studies have shown that the restoration of p53 activity alone can robustly induce tumor regression 1,2 , asserting the p53 pathway as a prime target for new cancer-drug development. Accordingly, a number of strategies for targeting wild-type p53 have been designed. These include restoring p53 function by antagonizing its negative regulator, the E3 ubiquitin ligase MDM2, using peptides and small molecules that have been shown to induce p53-dependent suppression of tumor cell growth in vitro and in vivo [3] [4] [5] . However, MDM2 inhibition alone may not be sufficient to potently activate p53 in the in vivo tumor microenvironment 6 .
a r t i c l e s
The p53 pathway is partially abrogated in more than one-half of tumors through the inactivation of various signaling or effector components. Several recent studies have shown that the restoration of p53 activity alone can robustly induce tumor regression 1, 2 , asserting the p53 pathway as a prime target for new cancer-drug development. Accordingly, a number of strategies for targeting wild-type p53 have been designed. These include restoring p53 function by antagonizing its negative regulator, the E3 ubiquitin ligase MDM2, using peptides and small molecules that have been shown to induce p53-dependent suppression of tumor cell growth in vitro and in vivo [3] [4] [5] . However, MDM2 inhibition alone may not be sufficient to potently activate p53 in the in vivo tumor microenvironment 6 .
It is well established that the level of p53 protein in cells is variable and is subtly regulated by ubiquitination and deubiquitination systems. HAUSP is a well-characterized deubiquitinase enzyme that has the ability to remove ubiquitin moieties from ubiquitinated substrates. It was initially identified as a binding partner of the herpes simplex virus (HSV) protein ICP0 that cooperatively facilitates viral replication 7 . Since then, further studies have shown that HAUSP can bind to various other substrates and is involved in the stress-response pathway, epigenetic silencing, neurodegenerative disorders and progression of infections by DNA viruses 8 . Additionally, HAUSP functions as a pivotal component of the p53-MDM2-MDMX signaling pathway, thus participating in the delicate balance that maintains p53 protein levels crucial for normal cellular homeostasis and diverse stress responses [9] [10] [11] . Notably, reduction or ablation of HAUSP leads to DNA damage-induced MDMX degradation and MDM2 instability, both of which robustly stabilize p53 (ref. 12) .
Structural analyses reveal that both p53 and MDM2 specifically recognize the N-terminal tumor necrosis factor receptor-associated factor (TRAF)-like domain of HAUSP, and HAUSP-binding elements were mapped to a peptide fragment in the C terminus of p53 and to a short peptide region preceding the acidic domain of MDM2 (refs. 13,14) . The cocrystal structures of the HAUSP TRAF-like domain in complex with these p53 and MDM2 short peptides demonstrate that the MDM2 peptide recognizes the same surface groove of HAUSP as that recognized by p53. However, the MDM2 peptide mediates more extensive interactions, indicating that MDM2, rather than p53, is the primary substrate of HAUSP under normal physiological conditions 13, 14 . An Epstein-Barr virus (EBV) viral protein, Epstein-Barr nuclear antigen 1 (EBNA1), also binds the same region of HAUSP as that bound by the MDM2 and p53 peptides, competitively blocking these cellular interactions 15, 16 . Thus, HAUSP seems to have multiple roles in regulating the p53-MDM2 pathway as well as in EBV-induced tumor cell survival, and it is therefore a potential chemotherapeutic target for p53-mediated suppression of tumor cell growth. In this report, we set out to answer the question of how viruses regulate HAUSP activity to escape the host's p53-mediated a r t i c l e s growth control. Here we describe the structural analysis of the Kaposi's sarcoma-associated herpesvirus (KSHV) vIRF4-HAUSP complex, and the discovery of two short viral peptides, vif1 and vif2, as potent, selective HAUSP antagonists.
RESULTS

Interaction between HAUSP and vIRF4 and complex structure
To study the HAUSP interaction network in KSHV (a γ-2 herpesvirus), we performed a yeast two-hybrid screen with a KSHV library 17 and MS analysis. Both studies independently discovered a previously unreported interaction between HAUSP and vIRF4 (Fig. 1a) . Detailed binding assays indicated that the HAUSP TRAF domain (HAUSP ) interacts specifically with vIRF4 (Fig. 1b-f ). An isothermal titration calorimetry (ITC) assay revealed a robust interaction between HAUSP 62-205 and vIRF4 , with a K d of 76 nM; this K d value is markedly higher than those reported for other HAUSP TRAF domain-binding substrates (K d = 0.5-15 µM) [13] [14] [15] 18 ( Supplementary Fig. 1a,b) .
To gain further insight into the molecular basis of the HAUSP-vIRF4 interaction, we crystallized the HAUSP 62-205 -vIRF4 153-256 complex using an in situ proteolysis technique 19 . We determined the three-dimensional structure of this crystallized complex by the molecular replacement method using the HAUSP TRAF domain structure (PDB 2F1W 13 ) as a search model, and refined to 1.6-Å resolution ( Fig. 2a and Table 1 ). All residues of HAUSP 62-205 except Asp62 are included in the final model, whereas only 15 residues (Ser202-Met216) of vIRF4 are visible in the electron density map (Supplementary Fig. 1c) . The overall structure of the HAUSP TRAF domain comprises a typical eight-stranded antiparallel β-sandwich fold (Fig. 2a) that forms a shallow groove in its surface structure (Fig. 2b, middle) . We observed no significant conformational changes between the peptide-free (PDB 2F1W 13 ) and vIRF4-bound TRAF domains, except that the C-terminal region of the TRAF domain was less extended upon vIRF4 binding (data not shown).
Detailed characterization of HAUSP TRAF-vIRF4 interaction
In contrast to previous studies that used synthetic or chimerically fused peptides of 4-10 amino acids in length in complex with the HAUSP TRAF domain [13] [14] [15] 18 , our in situ proteolysis treatment of the HAUSP 62-205 -vIRF4 153-256 protein complex yielded a crystal structure with a markedly longer 15-residue vIRF4 peptide. The peptide consisted of an upstream (Ser202-Asn208) and a downstream (Ala211-Met216) region, which are linked by Glu209 and Gly210 (Fig. 2a,b and Supplementary Fig. 1d ). The long peptide is positioned on the TRAF domain surface groove in a previously undescribed belt-type arrangement that threads through the left and right armholes (Fig. 2b,  middle) . This binding pattern is substantially different from that of other HAUSP substrates, which surround the left armhole of the TRAF domain (Fig. 2b, left) .
The downstream region (Ala211-Met216) of vIRF4 corresponds to the peptides previously reported for p53, MDM2, MDMX and EBNA1 to complex with HAUSP TRAF (Fig. 2b, right) . This region contains the well-conserved four-residue consensus sequence P/AXXS binding motif (Fig. 2b) . The equivalent motif of vIRF4 consists of Ala211, Ser212, Thr213 and Ser214 and engages in extensive polar and nonpolar interactions (Supplementary Fig. 1d ) with one side of the TRAF β-sheet, particularly the β7 strand (Fig. 2a) . Overall, the interaction pattern between HAUSP TRAF and the downstream region of vIRF4 is similar to those previously reported for other peptides [13] [14] [15] 18 ( Fig. 2b) . The upstream region (Ser202-Asn208) of vIRF4 binds to the HAUSP TRAF domain in a previously unreported extended conformation. This region participates in extensive interactions mainly with the other side of the β-sheet of the TRAF domain, especially the β6 strand (Fig. 2a,b) . TRAF Arg153 seems to have a decisive and unique role in TRAF's interaction with the upstream region of the vIRF4 peptide (Supplementary Fig. 1d ). On the other hand, vIRF4 Glu209 and Gly210 grasp the TRAF β6 and β7 strands (Fig. 2a,b and Supplementary Fig. 1d ). These observations indicate that the distinctive upstream region of the vIRF4 peptide may be vital for stabilizing the interaction of the downstream consensus region with the HAUSP TRAF domain. Indeed, ITC analysis showed that deletion of this upstream region (vIRF4 [209] [210] [211] [212] [213] [214] [215] [216] ) results in a decrease in TRAF binding affinity by a factor of 25 compared with vIRF4 [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] ( Supplementary Fig. 1a,b) , suggesting that vIRF4 uses a different interaction strategy from other HAUSP TRAF-binding cellular substrates as well as EBV EBNA1. Fig. 1a,b) . To evaluate whether vIRF4 competes with cellular substrates for binding to the HAUSP TRAF domain, we titrated each peptide (MDM2 137-152 , p53 [350] [351] [352] [353] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] or p53 [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] ) into the HAUSP TRAF domain, resulting in K a values of 9.1 × 10 4 M −1 , 6.5 × 10 4 M −1 and 6.7 × 10 4 M −1 , respectively (Fig. 2c) . When we subsequently titrated vIRF4 202-216 against HAUSP cellular substrates as a competitor, the observed association constant (K obs ) of each titration was markedly increased to 10.9 × 10 6 M −1 , 44.2 × 10 6 M −1 and 35.8 × 10 6 M −1 , respectively. These results indicate a considerably tighter interaction between the HAUSP TRAF domain and vIRF4 202-216 compared to HAUSP's interaction with its cellular substrates MDM2 and p53 ( Fig. 2c and Supplementary Fig. 2a) .
To further gauge the competitive nature of vIRF4 binding, we incubated the TRAF domain with an equimolar amount of vIRF4 in the presence of a five-fold molar excess of MDM2 137-152 , followed by size-exclusion chromatography analysis. The vIRF4 153-216 peptide still formed a stable complex with TRAF even in the presence of a fivefold molar excess of MDM2 peptide (Supplementary Fig. 2b ). This competitive nature of the vIRF4 153-216 peptide is probably due to its upstream region because the HAUSP binding affinity of the upstream region-deleted vIRF4 209-216 peptide (K d = 9.57 µM) was comparable to that of MDM2 [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] Fig. 1b ).
NMR analysis of the HAUSP-vIRF4 interaction
The ITC analysis results revealed that, whereas the TRAF binding affinity (K d = 0.54 µM) of vIRF4 Fig. 1b ). Taken together, these results indicate that, in addition to vIRF4 202-216 , the vIRF4 217-236 sequence has an important role in TRAF binding. 
a r t i c l e s
To further dissect these ITC results, we analyzed NMR chemical-shift perturbations of vIRF4 in the presence of HAUSP 62-205 (TRAF domain) or HAUSP 62-560 (TRAF and deubiquitinase (DUB) domain). Figure 3a shows the superposition of the 2D 1 H- 15 Fig. 3a) . (c) The Trp232 backbone assignment. Superposition of the 1 H-15 N correlation spectra of free vIRF4 (black) and vIRF4 (W232A) 153-256 (green). Residues located close to Trp232 were identified by comparing the two spectra (magenta arrows). The blue arrow indicates the assigned Trp232 backbone (see also Supplementary Fig. 3b ). (d) Proposed molecular interaction scheme between HAUSP and two different vIRF4-derived peptides. This model is based on the vIRF4-TRAF complex structure from the present study and the HAUSP structure containing the TRAF and DUB domains (PDB 2F1Z 13 ). The vIRF4 [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] peptide is shown as a magenta loop, and the vIRF4 217-236 peptide is depicted as a magenta short-dashed line. The catalytic triad (yellow) is highlighted in the catalytic site. The ubiquitin binding pocket is indicated. 
(min) (Fig. 3b , red, and Supplementary Fig. 3a) , consistent with crystal structure data showing that Trp204 is located in the TRAF-binding region of vIRF4 [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] . In contrast, the ε-NH signal of Trp232 was perturbed by binding of the TRAF DUB-containing HAUSP 62-560 but not by binding of the TRAF-containing HAUSP 62-205 (Fig. 3b, blue) . This latter result suggests that Trp232 is involved in the interaction of vIRF4 with the HAUSP DUB domain. We performed selective isotope ( 15 N) labeling of Trp232 to further identify backbone amide signals derived from residues located near Trp232, by comparing vIRF4 and a W232A mutant (Fig. 3c,  pink arrows, and Supplementary Fig. 3b) . Results indicate that the residues near Trp232 are involved in binding to the HAUSP catalytic DUB domain (Fig. 3a) . However, although vIRF4 and its peptide fragments (vIRF4 202-216 and vIRF4 220-236 ) were individually capable of interacting with HAUSP, neither peptide was able to bind to the HAUSP DUB domain alone (Fig. 1b, Supplementary Fig. 4a and data not shown), suggesting that a tight interaction with the N-terminal TRAF domain of HAUSP may be required for the binding of vIRF4 to the central DUB domain of HAUSP. These data suggest a bilateral mode of interaction between vIRF4 and HAUSP (Fig. 3d) wherein vIRF4 202-216 interacts with the HAUSP TRAF domain (primarily β6 and β7) with an unusually high binding affinity, and vIRF4 217-236 contacts the HAUSP DUB domain.
vIRF4 independently targets HAUSP and MDM2
As previously shown 20 , vIRF4 expression considerably increases MDM2 levels and consequently decreases p53 levels in TREx/BCBL-1 vIRF4 cells expressing AU epitope-tagged vIRF4 (AU-vIRF4) in a tetracyclineinducible manner. Unlike vIRF4, the vIRF4 1-605 mutant, which cannot interact with MDM2, did not induce MDM2 stabilization and p53 degradation, whereas the vIRF4 ∆202-256 mutant, which cannot interact with HAUSP, increased MDM2 levels and marginally decreased p53 levels ( Supplementary Fig. 4b,c) . Consistent with these endogenous p53 amounts, vIRF4 markedly induced p53 ubiquitination, the vIRF4 ∆202-256 mutant did so to a lesser extent, and the vIRF4 1-605 mutant did not do so (Supplementary Fig. 4c) . Thus, although vIRF4 interacts with both HAUSP and MDM2 to control p53 levels, the vIRF4-MDM2 interaction is more important in p53 downregulation than is the vIRF4-HAUSP interaction. 
a r t i c l e s
Inhibition of HAUSP DUB activity by vif1 and vif2 peptides
An in vitro DUB assay of immunopurified Flag-HAUSP complexes with Lys48-linked polyubiquitin chains of 3-7 ubiquitin moieties showed that vIRF4 effectively suppressed HAUSP DUB activity in a binding-dependent manner (Supplementary Fig. 5a ). To further assess the effects of these vIRF4 short sequences on HAUSP enzymatic activity, we mixed the vIRF4 peptides corresponding to residues 202-216 (hereafter referred to as 'vif1') and 220-236 (hereafter referred to as 'vif2') with purified HAUSP and then subjected them to an in vitro DUB assay with Lys48-or Lys63-linked 3-7 polyubiquitin chains. We included an ' Amp' peptide derived from the amphipathic helix sequence of the herpesvirus saimiri Tip protein 21 as a negative control. The vif2 peptide markedly suppressed HAUSP DUB activity, whereas the vif1 peptide minimally inhibited activity, and the Amp peptide had no effect on HAUSP DUB activity ( Supplementary  Fig. 5b ). Comparative kinetic analysis showed that whereas the vif1 peptide weakly attenuated HAUSP DUB activity, the vif2 peptide completely suppressed HAUSP DUB activity (Fig. 4a, right) . These results strongly support the idea that the vif2 peptide (residues 220-236) directly contacts the catalytic domain of HAUSP and thereby inhibit its DUB activity. To confirm the specificity of the vif1 and vif2 peptides toward HAUSP, we conducted an in vitro DUB assay using USP8, which is in the same family as HAUSP 22 . In contrast to what was observed for HAUSP DUSB, neither the vif1 peptide nor the vif2 peptide inhibited USP8 DUB activity (Fig. 4b) .
We then investigated whether the vif1 and vif2 peptides could inhibit HAUSP DUB activity against ubiquitinated substrates through substrate binding competition. To this end, we first generated ubiquitinated MDM2 using purified E1 (UBE1), E2 (UbcH5b) and E3 (MDM2) proteins and then performed an in vitro DUB assay using purified HAUSP alone or HAUSP preincubated with increasing amounts of each peptide ( Fig. 4c and Supplementary Fig. 5c ). The vif2 peptide efficiently blocked HAUSP enzymatic activity against both Lys48-linked polyubiquitin chains and ubiquitinated MDM2 (Fig. 4a,c) . In contrast to its ineffectiveness against Lys48-linked polyubiquitin chains, the vif1 peptide effectively blocked HAUSP DUB activity when we used ubiquitinated MDM2 as a substrate (Fig. 4c) . Incubation with the Amp peptide showed no effect on HAUSP DUB activity under the same conditions (Fig. 4c) .
To further delineate the vIRF4 peptides' action in vivo, we fused the vif1 and vif2 peptides with the HIV-1 TAT protein transduction domain for intracellular delivery 23, 24 and tested for their potential effects on in vivo HAUSP DUB activity. Consistent with the previous in vitro DUB assay, the TAT-vif2 peptide showed the strongest inhibitory activity toward ex vivo HAUSP enzymatic activity, but the TAT-vif1 peptide showed no effect under the same conditions (Fig. 4d) . These results thus further corroborate the notion that vif1 interferes with HAUSP substrate binding, whereas vif2 inhibits HAUSP DUB activity.
Antitumor activity of TAT-vif1 and TAT-vif2 peptides
Because HAUSP has a pivotal role in the regulation of the p53 pathway 10,11 , we investigated the potential effect of each peptide on KSHVinduced primary effusion lymphoma (PEL) tumor cell lines harboring wild-type p53 (Tp53 wt/wt ) 25, 26 . We included cell lines with mutated, nonfunctional p53 as controls. These results showed that time-dependent antiproliferative and cytotoxic activities differed depending on p53 status (Fig. 5a) . In contrast to treatment with the HIV-1 TAT peptide, which showed no effect on cell proliferation and cell death, incubation of PELs with various concentrations (25 µM, 50 µM or 100 µM) of the TAT-vif2 peptide not only robustly suppressed cell proliferation, but also induced profound cell death. The TAT-vif1 peptide did the same but with a much weaker activity than did the TAT-vif2 peptide (Supplementary Fig. 6a) . Notably, BJAB Burkitt lymphoma tumor cells carrying mutant p53 (ref. 27) continued to proliferate in the presence of the TAT-vif1 peptide and showed only minor growth retardation and cell death in the presence of the TAT-vif2 peptide (Fig. 5a) . The prostate cancer cell lines LnCap (Tp53 wt/wt ), PC3 (Tp53 -/-) and DU145 (Tp53 mt/mt ) 28 , which carry p53 genotypes with different degrees of function, showed the p53 dependence of TAT-vif1-and TAT-vif2-mediated cell death: LnCap cells, but not PC3 and DU145 cells, were highly susceptible to TAT-vif1-and TAT-vif2-mediated cell growth inhibition (Supplementary Fig. 6b ). Taken together, these data show that both the vif1 and vif2 peptides have vigorous cellkilling activities against (Tp53 wt/wt )-containing tumor cells.
One of the main cellular consequences of p53 activation in proliferating cells is cell-cycle arrest through transcriptional upregulation of the cyclin-dependent kinase inhibitor p21, which causes G 1 -S or G 2 -M cell-cycle arrest 29, 30 . Indeed, treatment of PEL cells with the TAT-vif1 or TAT-vif2 peptide markedly increased the G 1 -and G 2 -Mphase fraction and nearly completely depleted S-phase cells (Fig. 5b  and Supplementary Fig. 7) . Notably, we observed substantial sub-G 1 accumulation (reflecting cell death) in TAT-vif2-treated cells compared to TAT-or TAT-vif1-treated cells (Fig. 5b and Supplementary  Fig. 7, arrows) . Annexin V and propidium iodide staining assays showed that, although treatment with either the TAT-vif1 and TAT-vif2 peptides effectively induced apoptotic cell death in PEL cells carrying Tp53 wt/wt compared to TAT treatment, the TAT-vif2 peptide more a r t i c l e s rapidly and strongly induced apoptotic cell death than did the TATvif1 peptide ( Fig. 5c and Supplementary Fig. 8 ). Treatment of nutlin-3a, which blocks the interaction between MDM2 and p53 and thus induces extensive apoptosis, also led to considerable cell death, comparable to either peptide treatment.
As the inhibition of HAUSP enzymatic activity stabilizes and activates p53, we examined the effect of each peptide on intracellular levels of p53 and its transcriptional targets p21, MDM2, NOXA and PUMA. Incubation of exponentially growing PEL, LnCap and DU145 tumor cells with either peptide for 6 h led to increased p53, p21, MDM2, PUMA and NOXA at different levels ( Fig. 5d and Supplementary  Fig. 9 ). By contrast, BJAB cells exposed to the same conditions showed no detectable changes in p53, MDM2 and p21 levels. Neither the vif1 nor vif2 peptide altered HAUSP levels in various PEL cells or in BJAB cells ( Fig. 5d and Supplementary Fig. 9 ). These results show that the TAT-vif1 and TAT-vif2 peptides differentially affect the p53 pathway in cancer cells with functional (Tp53 wt/wt ).
vif1 and vif2 peptides induce in vivo tumor regression
To evaluate the in vivo antitumor activity of the vif1 and vif2 peptides, we used NOD/SCID xenograft mice intraperitoneally injected with BCBL-1 luciferase cells as previously described [31] [32] [33] . After being injected with the tumor cells, all of the mice developed PEL, with evident distention and ascites in the peritoneal cavity as well as markedly increased luminescence (data not shown). We challenged mice with advanced PEL with 1 mg (equivalent to ~100 µM) of each peptide on days 3, 5, 7, and twice weekly for subsequent weeks by intraperitoneal injection. Treatment with the TAT-vif1 or TAT-vif2 peptide led to little or no traceable luminescence with marked tumor regression ( Fig. 6  and Supplementary Fig. 10 ). The TAT-vif2 peptide caused particularly efficient and powerful tumor regression. By contrast, tumors continuously advanced in mice that received TAT peptide injections ( Fig. 6  and Supplementary Fig. 10 ). The mice treated with the TAT-vif1 or TAT-vif2 peptide showed neither significant weight loss nor any gross abnormalities upon necropsy at the end of the treatment. These results collectively demonstrate the in vivo antitumor activity of the TAT-vif1 and TAT-vif2 peptides.
Combining vif1 and vif2 peptides increases antitumor activity
Owing to their bilateral inhibition of HAUSP activity, treatment with the TAT-vif1 and TAT-vif2 peptides combined caused considerable increases in antitumor activity: treatment with 25 µM TAT-vif1 and 25 µM TAT-vif2 was highly effective in inducing p53-dependent cell growth suppression, cell-cycle arrest and cell death, which was concordant with 100 µM treatment with the TAT-vif1 or TATvif2 peptides individually ( Fig. 7 and Supplementary Fig. 11a,b) . 
a r t i c l e s
Furthermore, incubation of exponentially growing PELs cells with the TAT-vif1 and TAT-vif2 combination (25 µM of each) for 6 h robustly increased the levels of p53, p21 and MDM2 ( Fig. 7b and Supplementary Fig. 11c ). We observed marked tumor regression when we challenged NOD/SCID mice with advanced PEL with the TAT-vif1 and TAT-vif2 peptide combination (each at a dose of 0.25 mg, equivalent to ~25 µM) (Fig. 7e) . These results demonstrate the enhanced antitumor activity of the TAT-vif1 and TAT-vif2 peptides when combined.
DISCUSSION
To bypass IFN-and p53-mediated irreversible cell-cycle arrest and apoptosis, and to complete its life cycle, KSHV has developed a unique mechanism for antagonizing cellular IFN-and p53-mediated host innate immune responses by incorporating viral homologs of cellular IFN regulatory factors (IRFs), called vIRFs. KSHV encodes four vIRFs in a cluster region that have two common biological functions contributing to host immune evasion: the inhibition of host IFNmediated innate immunity and the deregulation of p53-mediated tumor-suppressive activity 34, 35 . We previously reported that KSHV vIRF4 interacts with MDM2 through its C-terminal region, leading to inhibition of MDM2 autoubiquitination and stabilization of its protein levels, thus enhancing MDM2-mediated p53 degradation 20 . Here we show that vIRF4's actions with HAUSP and MDM2 are functionally and genetically separable, and that the vIRF4-MDM2 interaction is more important in downregulating p53 than is the vIRF4-HAUSP interaction. Thus, KSHV vIRF4 has evolved to target two components, MDM2 and HAUSP, of the p53 pathway to comprehensively suppress p53 function. This suggests that vIRF4 affects p53 tumor suppressor-mediated surveillance in a similar but distinct way from other viral proteins such as the EBV EBNA1. Last, it should be noted that vIRF4 circumvents host growth surveillance to enhance viral replication in infected cells in a manner reminiscent of HSV ICP0 and EBV EBNA1, which also direct HAUSP to promote viral replication and oncogenic processes, respectively 7, 15 . Thus, HAUSP seems to be a common host target for human herpesviruses to support their life cycle and pathogenesis and hence is considered to be a potential target for antiviral therapy. Using crystal structure analysis facilitated by in situ proteolysis, together with ITC assessment, we demonstrate that, although KSHV vIRF4 (residues ~210-216) binds to the same surface groove of the HAUSP TRAF domain as that recognized by MDM2 and p53, it uses a HAUSP interaction strategy different from that of MDM2 and p53. Beside residues 210-216, vIRF4 uses an additional short upstream region (residues 202-208) to interact extensively with the other side of the TRAF domain β-sheet, especially the β6 strand (Fig. 2a,b) . It is this extra interaction property of vIRF4 that results in a much higher binding affinity to the HAUSP TRAF domain than those of MDM2 or p53.
Notably, in a study using a comparably designed peptide EBNA1 435-449 containing the P/AXXS motif and sequences equivalent to the vIRF4 upstream region, EBV EBNA1 435-449 showed a similar HAUSP TRAF binding affinity (K d = 0.48 µM) to that of the vIRF4 202-216 peptide (K d = 0.39 µM) (Supplementary Fig. 1b) . However, NMR chemical shift mapping analysis showed that, unlike for the vIRF4 peptide, the EBNA1 sequences corresponding to the upstream region of the vIRF4 peptide did not affect its interaction with the HAUSP TRAF domain 15 . This result suggests that KSHV vIRF4 and EBV EBNA1 target HAUSP in similar but distinct manners. It is worth noting that EBNA1 is the only HAUSP TRAF-binding substrate with a charged side chain residue, Glu444, at the position of 'P/A' in the motif P/AXXS motif ( Supplementary Fig. 1b and Fig. 2b ).
This residue seems to be crucial to how EBNA1 attains a higher binding affinity for HAUSP TRAF than do cellular substrates, as the Glu444 side chain interacts with the backbone amide and carbonyl group of Ser155 and Arg153 on the β6 strand, respectively, through bridging water molecules, as well as with the indole nitrogen of TRAF Trp165 (Supplementary Fig. 1e) . Moreover, EBNA1 uses four backbonebackbone interactions with the Trp165-Asn169 residues on the TRAF β7 strand (Supplementary Fig. 1e) , whereas cellular substrates use only two main chains to interact with the same TRAF strand (data not shown). As a consequence, the EBNA1 peptide may compete with cellular substrates even though they use similar HAUSP TRAF-binding patterns (Fig. 2b) . These competences of EBNA1 may collectively result in an effect comparable to that seen with vIRF4 202-216 to manage HAUSP interactions with cellular substrates. Furthermore, independently of its inhibition of p53-mediated apoptosis, the EBNA1-HAUSP interaction is also involved in PML disruption to promote the survival of cells with DNA damage 36 . Thus, two human gamma herpesviruses have evolved to target and deregulate HAUSP function and its related pathways, but the consequences of their action may be substantially different.
Along with the structure of the HAUSP TRAF-DUB domain 13 , our ITC, NMR and deubiquitinase enzyme analyses suggest that a peptide of ~17 amino acids (residues 216-232) may be long enough to stretch from the TRAF domain to the DUB domain of HAUSP, and additional sequences around residues 232-236 may directly contact the catalytic core site of HAUSP, resulting in the robust inhibition of its enzymatic activity. Because of these exceptional properties of vIRF4, the vif1 and vif2 peptides clearly posses two provocative and effective strategies that make them specific and robust HAUSP antagonists: the vif1 peptide binds to the HAUSP TRAF domain with the highest affinity among all reported substrates, blocking TRAF binding by cellular substrates, whereas the vif2 peptide seems to loosely bind the TRAF domain and the active catalytic site of the DUB domain of HAUSP, suppressing its DUB enzymatic activity. Consequently, the vif1 and vif2 peptides comprehensively suppress HAUSP activity, effectively restore p53-dependent apoptosis in wild-type p53-carrying cancer cells, and suppress tumor growth in mouse xenograft models. Our study not only provides strong evidence that the vif1 and vif2 peptides are ideal for abolishing HAUSP activity but also shows that they have the potential to be therapeutically beneficial reagents against p53 wild-type tumors. However, we should stress that the vIRF4 peptides studied here do not reflect the authentic biology of full-length vIRF4, which targets both HAUSP and MDM2 to comprehensively inactivate host p53-mediated surveillance. Thus, the therapeutic exploitation of the vIRF4 peptides as HAUSP inhibitors should be uncoupled from the biological function of vIRF4 as a survival factor against the host's immune surveillance programs.
Notably, because HAUSP contains a well-conserved catalytic core domain, it should therefore be a more tractable as a drug target than blocking the p53-MDM2-MDMX interaction. This is underscored by recent findings showing that HAUSP can be used to therapeutically target p53-independent apoptosis responses in certain tumors. For instance, the loss of HAUSP in colorectal cancer cells potentiates apoptotic cell death by inducing proteasomal degradation of DNMT1, further compounding the potential of HAUSP inhibition as an effective anticancer therapy [37] [38] [39] [40] . Accordingly, because we cannot exclude the possibility that HAUSP regulates the function of other known or as-yet-unknown substrates involved in p53-independent apoptosis, our peptides may have additional off-target, p53-independent proapoptotic effects.
Our study shows that the vIRF4-derived short vif1 and vif2 peptides comprehensively suppress HAUSP activity, effectively restoring a r t i c l e s p53-dependent apoptosis in wild-type p53-carrying cancer cells and suppressing tumor growth in a mouse xenograft model. Most notably, we herein report that the vif1 and vif2 peptides represent potential new chemotherapeutic molecules for anticancer therapies. 
METHODS
Methods
